Publication on Tenapanor in IBS-C Patients Linked to Linaclotide Record

On October 11, 2026, a new publication appeared in the journal Digestive Diseases and Sciences. The paper is titled "Efficacy of Tenapanor in Patients With or Without Prior Use of IBS-C Prescription Medications: A Post-hoc Analysis of Phase 3 Clinical Trials." This entry is cataloged under linaclotide, a compound with approved regulatory status, as part of ongoing tracking of literature relevant to IBS-C treatment options. The publication is identified as a post-hoc analysis drawing on data from Phase 3 clinical trials. No findings, outcomes, or efficacy results from the analysis are included in this notice. The record reflects only the existence and bibliographic details of the publication as provided. Readers interested in the full scope of the post-hoc analysis, including any reported results, should consult the original article directly through the journal. This brief does not characterize or interpret the study's conclusions. For more background on linaclotide, including its approved uses and regulatory history, readers can refer to the compound overview.